IPHA Stock Summary and Trading Ideas (Innate Pharma S.A. - American Depositary Shares | NASDAQ:IPHA)

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Innate Pharma S.A. - American Depositary Shares trades on the NASDAQ stock market under the symbol IPHA.

As of April 27, 2026, IPHA stock price declined to $1.40 with 9,827 million shares trading.

IPHA has a beta of 0.89, meaning it tends to be less sensitive to market movements. IPHA has a correlation of 0.05 to the broad based SPY ETF.

IPHA has a market cap of $131.33 million. This is considered a Micro Cap stock.

Last quarter Innate Pharma S.A. - American Depositary Shares reported $10 million in Revenue and -$.64 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.01.

In the last 3 years, IPHA traded as high as $3.57 and as low as $1.17.

IPHA has underperformed the market in the last year with a price return of -29.3% while the SPY ETF gained +31.2%. IPHA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -21.3% and -2.8%, respectively, while the SPY returned +3.1% and +4.2%, respectively.

IPHA support price is $1.33 and resistance is $1.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IPHA shares will trade within this expected range on the day.